| __timestamp | BioMarin Pharmaceutical Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 5114000 |
| Thursday, January 1, 2015 | 402271000 | 13403000 |
| Friday, January 1, 2016 | 476593000 | 31056000 |
| Sunday, January 1, 2017 | 554336000 | 35845000 |
| Monday, January 1, 2018 | 604353000 | 48294000 |
| Tuesday, January 1, 2019 | 680924000 | 63488000 |
| Wednesday, January 1, 2020 | 737669000 | 88208000 |
| Friday, January 1, 2021 | 759375000 | 102802000 |
| Saturday, January 1, 2022 | 854009000 | 102464000 |
| Sunday, January 1, 2023 | 937300000 | 76162000 |
| Monday, January 1, 2024 | 1009025000 | 72977000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and CRISPR Therapeutics AG have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. BioMarin's SG&A expenses have surged by over 200% from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, CRISPR Therapeutics AG, a relatively newer player, has seen its SG&A expenses grow by approximately 1,400% during the same period, indicative of its rapid growth and investment in groundbreaking gene-editing technologies. By 2023, BioMarin's expenses were nearly 12 times higher than CRISPR's, highlighting the different stages of maturity and market strategies of these companies. This financial insight not only underscores the competitive landscape but also offers a glimpse into the strategic priorities shaping the future of biotechnology.
Biogen Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Alpine Immune Sciences, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Wave Life Sciences Ltd. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Galapagos NV